Answers are grounded in this paper and cite their sources.
Corrigendum to: “EASL clinical practice guidelines: Management of chronic hepatitis B virus infection” [J Hepatol 2012;57:167–185]Journal of HepatologyVol. 58Issue 1PreviewRevision of Table 5 of the recent EASL HBV Clinical Practice Guidelines which included the cross-resistance data for the most frequent resistant HBV variants [Table 5 (revised)] These changes do not affect the strength of clinical evidence and the recommendations for the clinical management of patients who develop HBV resistance during therapy with nucleos(t)ide analogues.
No takes yet. Share an insight, caveat, or question.
A 2012 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: